ANY LAB TEST NOW

Item 7 pegs the initial investment at $144,900-$271,900, with a $40,000 franchise fee covering training and site selection support. Monthly royalties hit 8% of gross sales (minimum $500), plus 1% into the national ad fund and $220-$1,015 for software, tech, and optional call center services. Crucially, Item 19 discloses average gross revenue of $339,892 and median $324,667 for 2023, based on mature units—solid figures for a cash-only model dodging insurance delays. The 221 franchise locations (7 corporate-owned) grew 7% year-over-year from 207 in 2022, with 21 projected new units signaling committed expansion since franchising began in 2004.

System health looks resilient: 13 transfers last year point to a liquid resale market rather than distress, no major terminations noted, and steady +7% growth outpaces many service brands. These revenues on a sub-$300K startup suggest strong cash flow potential—likely $70K-$100K EBITDA after fees and ops if margins mirror industry norms for lab services (25-35%). For hands-on operators eyeing direct-to-consumer health niches, the no-insurance barrier creates pricing power and walk-in convenience, but success hinges on high-traffic locations and marketing draw in your territory.